Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26011545 | 0.85 | CACNA1H (0.38) | HTR2AHTR2CCRHR1LMNATP53 | |
| SCHEMBL25745801 | 0.79 | ACHE (0.41) | HTR2AHTR2CCRHR1HPGDPTGS2 | |
| SCHEMBL19803230 | 0.79 | HTR1D (0.35) | HTR2AHTR2CLMNATP53CYP3A4 | |
| SCHEMBL16009749 | 0.79 | HTR2A (0.39) | HTR2AHTR2CCRHR1 | |
| SCHEMBL22017132 | 0.79 | HTR2A (0.39) | HTR2AHTR2CCRHR1PTGS2PDE3B | |
| SCHEMBL19871663 | 0.78 | HTR2A (0.38) | HTR2AHTR2CLMNAPTGS2 | |
| SCHEMBL21766572 | 0.72 | CACNA1H (0.37) | CYP3A4 | |
| SCHEMBL13073510 | 0.72 | HTR2A (0.43) | HTR2AHTR2CLMNATP53CYP3A4 | |
| SCHEMBL12012739 | 0.72 | HTR2A (0.41) | HTR2AHTR2CHPGDALOX15 | |
| SCHEMBL26012392 | 0.71 | CACNA1H (0.35) | HTR2AHTR2CCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | HTR2A 1660/4885HTR2C 1031/4885CRHR1 3851/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | HTR2A 1660/4885HTR2C 1031/4885CRHR1 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.